From Investing.com: 2024-05-19 09:05:08

Vivos Therapeutics reported a $3.4 million revenue for Q1 2024, a decrease from the previous year. Despite the decline in VIP enrollments and appliance sales, the company achieved a gross profit of $1.9 million with a 57% margin. Operating expenses decreased by 22%, showing progress towards profitability. CEO Kirk Huntsman remains positive about Vivos’ growth prospects.

In Q1 2024, Vivos enrolled 50 VIPs, up from 36 in the same period last year. Gross profit reached $1.9 million with a 57% margin. Operating expenses were reduced by 22%, leading to a lower operating loss. Vivos aims to achieve cash flow positivity by late 2024 or early 2025.

Vivos Therapeutics is focused on becoming cash flow positive by the end of 2024 or early 2025. The company is introducing new strategic initiatives to enhance product access. Collaborations with the medical and sleep testing communities are expected to stimulate revenue growth and improve patient outcomes. FDA clearance for severe sleep apnea treatment has boosted credibility and opened up new opportunities for Vivos.

Vivos’ financial metrics reveal a mixed performance in Q1 2024, with revenue declining compared to the previous year. Although the company is making progress in cost management and revenue diversification, profitability remains a challenge. Vivos’ cash position is strong, but analysts do not foresee profitability in the near term. Strategic initiatives and partnerships may drive future growth for the company.



Read more at Investing.com: Vivos Therapeutics reports mixed Q1 results, aims for growth By Investing.com